Bispecific Antibodies Market By Applications (Infectious Diseases, Bacterial Infections, Viral Infections, Cancer Diagnostic, Signaling Pathways, Tumor Angiogenesis, Gene Therapy), By Product (Quadromas, Chemical heteroconjugates), Industry Trends, Estimation & Forecast, 2017 - 2025

  • Published On: Jul, 2018
  • Category: Healthcare
  • Pages: 182
Bispecific antibodies market is expected to grow with a CAGR of XX% during the forecast period of 2018 to 2025.

Market Overview:

Bispecific antibodies (BsAbs) or bispecific immunoglobulins, are the artificially constructed protiens, which can bind to two different antigen sites at one time. The market for bispecific antibodies is still in its nascent stage and has not witnessed a significant penetration within the healthcare industry till yet. Removab® was the first trifunctional antibody which was approved by the European Medicines Agency for treating malignant ascites in 2009. However, its marketing authorization was withdrawn in the EU at the request of Neovil Biotech GmbH in 2017. In the current scenario, around 60 drugs are being tested in preclinical trials and 30 in clinical trials, out of which nearly 67% of these are intented for the cancer treatment. Constantly increasing cases of Acute Lymphocytic Leukemia (ALL) is emerging out as the major driving factor for the market growth. The bispecific blinatumomab molecule, which was developed by using diabody technology is now being extensively used for curing acute lymphocytic leukemia (ALL). Moreover, these bispecific antibodies have been also found highly efficient in the treatment of various types of cancer such as breast cancer, cervical cancer and lung cancer. As per the data revealed by American Cancer Society, America is estimated to witness 5,960 new cases of ALL, comprising of 3,290 male cases and 2,670 female cases, in the current year. However, certain challenges such as stringent regulations, coupled with high cost involved in research and development activities of these drugs are expected to hinder the market growth. On the other hand, continuous R&D and successful approvals of advanced bispecific antibodies is anticipated to generate lucrative opportunities for the leading manufacturers. Ozoralizumab, a nanobody, has recently completed its phase-2 clinical trial and its administration has shown a significant improvement in the patients suffering with rheumatoid arthritis (RA). Collaboration and product launch have emerged out as some of the most adopted strategies among the major market players in order to expand their businesses and strengthen their foothold within the market. In April 2018, Zymeworks and Celgene have gone through a collaboration owing to the intensification of research & development, and commercialization of bispecific antibody therapeutics. This collaboration has enabled Celgene to research and develop multiple bispecific antibodies based on Zymeworks’ Azymetric™ platform. The report provides detailed qualitative and quantitative analysis of the bispecific antibodies market. Market size and forecast has been provided for the period - (2018 - 2025), for the segments namely product and application in each of the major regions.

Bispecific Antibodies Market Segmentation

By Applications  • Infectious Diseases • Bacterial Infections • Viral Infections • Cancer Diagnostic • Signaling Pathways • Tumor Angiogenesis • Gene Therapy By Product • Quadromas • Chemical heteroconjugates • Others By Geography • North America o U.S. o Canada o Mexico • Europe o U.K. o France o Germany o Italy o Spain o Rest of Europe • Asia-Pacific o China o Japan o India o Korea o Rest of APAC • South America o Brazil o Rest of South America • Rest of the World o Middle East o Africa

CHAPTER 1. INTRODUCTION
1.1. RESEARCH METHODOLOGY
1.1.1. ERC desk research
1.1.2. ERC data synthesis
1.1.3. Data validation and market feedback
1.1.4. ERC data sources
CHAPTER 2. BISPECIFIC ANTIBODIES MARKET OVERVIEW
2.1. BISPECIFIC ANTIBODIES MARKET INTRODUCTION
2.4. GLOBAL BISPECIFIC ANTIBODIES MARKET REVENUE AND GROWTH RATE, 2017-2025
CHAPTER 3. GLOBAL BISPECIFIC ANTIBODIES MARKET BY PRODUCT, 2017-2025
3.1. QUADROMAS
3.2. CHEMICAL HETEROCONJUGATES
3.3. OTHERS
3.4. GLOBAL BISPECIFIC ANTIBODIES MARKET REVENUE BY PRODUCT, 2017-2025
3.4.1. Global Bispecific Antibodies Market Revenue (Million USD) and Share (%) By Product, 2017-2025
3.4.2. Quadromas Market Revenue and Growth Rate, 2017-2025
3.4.3. Chemical heteroconjugates Market Revenue and Growth Rate, 2017-2025
3.4.4. Others Market Revenue and Growth Rate, 2017-2025
CHAPTER 4. GLOBAL BISPECIFIC ANTIBODIES MARKET BY APPLICATION, 2017-2025
4.1. INFECTIOUS DISEASES
4.2. BACTERIAL INFECTIONS
4.3. VIRAL INFECTIONS
4.4. CANCER DIAGNOSTIC
4.5. SIGNALING PATHWAYS
4.6. TUMOR ANGIOGENESIS
4.7. GENE THERAPY
4.8. GLOBAL BISPECIFIC ANTIBODIES MARKET REVENUE BY APPLICATION, 2017-2025
4.8.1. Global Bispecific Antibodies Market Revenue (Million USD) and Share (%) By Application, 2017-2025
4.8.2. Infectious Diseases Market Revenue and Growth Rate, 2017-2025
4.8.3. Bacterial Infections Market Revenue and Growth Rate, 2017-2025
4.8.4. Viral Infections Market Revenue and Growth Rate, 2017-2025
CHAPTER 5. GLOBAL BISPECIFIC ANTIBODIES MARKET BY REGION, 2017-2025
5.1. NORTH AMERICA
5.1.1. U.S.
5.1.2. Canada
5.1.3. Mexico
5.2. EUROPE
5.2.1. U.K.
5.2.2. France
5.2.3. Germany
5.2.4. Italy
5.2.5. Spain
5.2.6. Rest of Europe
5.3. ASIA PACIFIC
5.3.1. China
5.3.2. Japan
5.3.3. India
5.3.4. Korea
5.3.5. Rest of APAC
5.4. SOUTH AMERICA
5.4.1. Brazil
5.4.2. Rest of South America
5.5. REST OF THE WORLD
5.5.1. Middle East
5.5.2. Africa
5.6. GLOBAL BISPECIFIC ANTIBODIES MARKET REVENUE BY REGION, 2017-2025
5.6.1. Global Bispecific Antibodies Market Revenue (Million USD) and Share (%) By Region, 2017-2025
5.6.2. North America Market Revenue and Growth Rate, 2017-2025
5.6.3. Europe Market Revenue and Growth Rate, 2017-2025
5.6.4. Asia Pacific Market Revenue and Growth Rate, 2017-2025
5.6.5. South America Market Revenue and Growth Rate, 2017-2025
5.6.6. Rest of the World Market Revenue and Growth Rate, 2017-2025
CHAPTER 6. VALUE CHAIN ANALYSIS
CHAPTER 7. MARKET DETERMINANTS
7.1. MARKET DRIVERS
7.2. MARKET RESTRAINTS
7.3. MARKET OPPORTUNITIES
7.4. MARKET DETERMINANTS RADAR CHART
CHAPTER 8. GLOBAL BISPECIFIC ANTIBODIES MARKET COMPETITION BY MANUFACTURERS
8.1. GLOBAL BISPECIFIC ANTIBODIES PRODUCTION AND SHARE BY MANUFACTURERS (2017-2025)
8.1.1. Global Bispecific Antibodies Production (VOLUME) and Share (%) by Manufacturers (2017-2025)
8.2. GLOBAL BISPECIFIC ANTIBODIES REVENUE AND SHARE BY MANUFACTURERS (2017-2025)
8.2.1. Global Bispecific Antibodies Revenue (Million USD) and Share (%) by Manufacturers (2017-2025)
8.3. BISPECIFIC ANTIBODIES MARKET COMPETITIVE SITUATION AND TRENDS
8.3.1. Bispecific Antibodies Market Share (%) of Top 3 Manufacturers
8.3.2. Bispecific Antibodies Market Share (%) of Top 5 Manufacturers
CHAPTER 9. GLOBAL BISPECIFIC ANTIBODIES COMPANY ANALYSIS
9.1. ABBVIE
9.1.1. Business Overview
9.1.2. Company Basic Information
9.1.3. Bispecific Antibodies Product Details
9.1.4. AbbVie Bispecific Antibodies Revenue and Gross Margin
9.2. JANSSEN BIOTECH
9.2.1. Business Overview
9.2.2. Company Basic Information
9.2.3. Bispecific Antibodies Product Details
9.2.4. Janssen Biotech Bispecific Antibodies Revenue and Gross Margin
9.3. AMGEN, INC.
9.3.1. Business Overview
9.3.2. Company Basic Information
9.3.3. Bispecific Antibodies Product Details
9.3.4. Amgen, Inc. Bispecific Antibodies Revenue and Gross Margin
9.4. BAYER AG
9.4.1. Business Overview
9.4.2. Company Basic Information
9.4.3. Bispecific Antibodies Product Details
9.4.4. Bayer AG Bispecific Antibodies Production, Revenue and Gross Margin
9.5. IMMUNOCORE LIMITED
9.5.1. Business Overview
9.5.2. Company Basic Information
9.5.3. Bispecific Antibodies Product Details
9.5.4. Immunocore Limited Bispecific Antibodies Revenue and Gross Margin
9.6. CELGENE
9.6.1. Business Overview
9.6.2. Company Basic Information
9.6.3. Bispecific Antibodies Product Details
9.6.4. Celgene Bispecific Antibodies Revenue and Gross Margin
9.7. GANYMED PHARMACEUTICALS
9.7.1. Business Overview
9.7.2. Company Basic Information
9.7.3. Bispecific Antibodies Product Details
9.7.4. Ganymed Pharmaceuticals Bispecific Antibodies Revenue and Gross Margin
9.8. ONCOMED PHARMACEUTICALS
9.8.1. Business Overview
9.8.2. Company Basic Information
9.8.3. Bispecific Antibodies Product Details
9.8.4. OncoMed Pharmaceuticals Bispecific Antibodies Revenue and Gross Margin

9.9. PAKTIS ANTIBODY SERVICES GMBH
9.9.1. Business Overview
9.9.2. Company Basic Information
9.9.3. Bispecific Antibodies Product Details
9.9.4. Paktis Antibody Services GmbH Bispecific Antibodies Revenue and Gross Margin
9.10. FABION PHARMACEUTICAL
9.10.1. Business Overview
9.10.2. Company Basic Information
9.10.3. Bispecific Antibodies Product Details
9.10.4. Fabion Pharmaceutical Bispecific Antibodies Revenue and Gross Margin

• AbbVie
• Janssen Biotech
• Amgen, Inc.
• Bayer AG
• Immunocore Limited
• Celgene
• Ganymed Pharmaceuticals
• OncoMed Pharmaceuticals
• Paktis Antibody Services GmbH
• Fabion Pharmaceutical
• Merck & Co., Inc.
• Dow Pharmaceutical Solutions
• ImmunGene, Inc., Novartis AG,
• Pfizer, Inc.
• F. Hoffmann-La Roche AG

Select License Type

  • $4700
  • $5600
  • $2000
  • Buy Now

Report Highlights:

Complete overview of market
Major drivers, restrain, opportunities, and challenges of the market
Market Trends and how they are boosting the market growth
Changing dynamics in the Market
Complete overview of the market
Historical, Base year, projected, and current market size in terms of value and volume
COVID-19 Impact analysis of the market
Current industry trends and developments

CLIENTS